Pendulum Therapeutics

About:

Pendulum Therapeutics is a biotechnology firm improving health through products targeting the microbiome.

Website: https://pendulumlife.com

Twitter/X: Pendulum_Co

Top Investors: Khosla Ventures, Alumni Ventures, Sequoia Capital, Mayo Clinic, Felicis

Description:

Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.

Total Funding Amount:

$121M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2013-01-01

Founders:

Colleen Cutcliffe, James H. Bullard, John S. Eid

Number of Employees:

11-50

Last Funding Date:

2024-02-20

IPO Status:

Private

Industries:

© 2025 bioDAO.ai